The two Netherlands-based firms will market their joint offering to pharmaceutical companies and others researching immune system-related diseases.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
An analysis of B cell adaptive immune receptor sequences in 10 individuals uncovered exceptionally diverse antibody repertoires with a subset of shared antibody clonotypes.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
Researchers will use Adaptive's immune repertoire sequencing technology to look for a molecular signature of type 1 diabetes.
A new analysis of immune cells in breast carcinomas and matched blood, breast, and lymph tissue uncovered phenotypic expansions in tumor immune cell populations.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.